Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Hits New 12-Month High – What’s Next?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) hit a new 52-week high during trading on Monday. The company traded as high as $51.05 and last traded at $51.05, with a volume of 100 shares trading hands. The stock had previously closed at $46.00.

Analyst Upgrades and Downgrades

BIOVF has been the subject of several recent research reports. Nordea Equity Research downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, October 22nd. Pareto Securities raised shares of Swedish Orphan Biovitrum from a “hold” rating to a “buy” rating in a report on Tuesday, October 27th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Finally, HC Wainwright reissued a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Wednesday, October 28th. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

The company has a debt-to-equity ratio of 0.20, a current ratio of 0.88 and a quick ratio of 0.55. The company has a 50-day moving average price of $45.82 and a 200-day moving average price of $44.43. The firm has a market capitalization of $18.17 billion, a PE ratio of 25.40 and a beta of 0.48.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options.

Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.

The company was formed in 2010 when Biovitrum acquired Swedish Orphan and adopted the Swedish Orphan Biovitrum name.